The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Bayer; Eisai; GlaxoSmithKline; Lilly; Mundipharma; Pfizer; PharmaMar
Research Funding - Adaptimmune (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Novartis; Pfizer; PharmaMar; ROVI
Identification of response stratification factors from pooled efficacy analyses of afamitresgene autoleucel (“Afami-cel” [Formerly ADP-A2M4]) in metastatic synovial sarcoma and myxoid/round cell liposarcoma phase 1 and phase 2 trials.
 
Sandra P. D'Angelo
Honoraria - Adaptimmune; GlaxoSmithKline; Pfizer; Rain Therapeutics; SERVIER
Consulting or Advisory Role - Adaptimmune; GlaxoSmithKline; Nektar; Pfizer; Rain Therapeutics; Rain Therapeutics; Servier
 
Steven Attia
Research Funding - AB Science (Inst); Adaptimmune (Inst); Advenchen Laboratories (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); BTG (Inst); CBA Pharma (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); FORMA Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gradalis (Inst); Immune Design (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Philogen (Inst); PTC Therapeutics (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); TRACON Pharma (Inst); TRACON Pharma (Inst)
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - AstraZeneca; Bayer; BMS; Deciphera; Ignyta; MSD; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera; Karyopharm Therapeutics; Pharmamar; Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); DEciphera (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); OSE Pharma (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Sandra J. Strauss
Consulting or Advisory Role - Ceridwen Oncology; GlaxoSmithKline
 
Claudia Maria Valverde Morales
No Relationships to Disclose
 
Albiruni Ryan Abdul Razak
Consulting or Advisory Role - Adaptimmune; Bayer; GlaxoSmithKline; Inhibrx; Medison
Research Funding - Abbvie; Adaptimmune; Amgen; Blueprint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Deciphera; GlaxoSmithKline; Iterion Therapeutics; Karyopharm Therapeutics; MedImmune; Merck; Neoleukin Therapeutics; Pfizer; Rain Therapeutics; Roche/Genentech; Symphogen
Expert Testimony - Medison
 
Erin Van Winkle
Employment - Adaptimmune
Stock and Other Ownership Interests - Adaptimmune
 
Thejo Annareddy
Employment - Adaptimmune
Stock and Other Ownership Interests - Adaptimmune
 
Chandra Sattigari
Employment - Adaptimmune
Stock and Other Ownership Interests - Adaptimmune
 
Evangelo Diamantopoulos
Employment - Adaptimmune
Stock and Other Ownership Interests - Adaptimmune
 
Dennis Williams
Employment - Adaptimmune
Stock and Other Ownership Interests - Adaptimmune
 
Elliot Norry
Employment - Adaptimmune
Stock and Other Ownership Interests - Adaptimmune
 
Swethajit Biswas
Employment - Adaptimmune
Stock and Other Ownership Interests - Adaptimmune
 
Dejka M. Araujo
Research Funding - Adaptimmune (Inst); GlaxoSmithKline (Inst); Immatics (Inst)
 
Brian Andrew Van Tine
Leadership - Polaris
Honoraria - Bionest Partner; Horizon CME; Research to Practice; Targeted Oncology
Consulting or Advisory Role - Adaptimmune; ADRx; Apexigen; Ayala Pharmaceuticals; Bayer; Cytokinetics; Daiihi Sankyo; Deciphera; EMD Serono; Epizyme; GlaxoSmithKline; Immune Design; Intellisphere; Lilly; Novartis; Pfizer
Speakers' Bureau - Adaptimmune; GlaxoSmithKline; Lilly; Novartis
Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; GlaxoSmithKline; Lilly